Regulus Therapeutics Inc.

Ownership Transactions Reported by 14 Insiders

Symbol
RGLS on Nasdaq
Location
4224 Campus Point Court, Suite 210, San Diego, CA

Insiders trading volume in the past year

Regulus Therapeutics Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Stelios Papadopoulos Director $1.57M May 20, 2024
Joseph P. Hagan Chief Executive Officer, Director $283K -$106K -27.3% Jan 30, 2025
Denis Drygin Chief Scientific Officer $119K Mar 1, 2022
Christopher Aker Sr. VP & General Counsel $62.6K -$55.1K -46.8% Jan 30, 2025
Crispina Calsada Chief Financial Officer $57.4K -$55.3K -49.1% Jan 30, 2025
Preston Klassen President & Head of R & D, Director $45.5K -$39.7K -46.6% Jan 30, 2025
David Baltimore Director $23.5K +$20.8K +766% Jan 30, 2025
Kathryn J. Collier Director $12.3K +$7.28K +146% Jul 25, 2024
Hugh Rosen Director May 20, 2024
Alice Shih-hou Huang Director May 20, 2024
Simos Simeonidis Director Jun 9, 2022
Pascale Witz Director May 20, 2024
William H. Rastetter Director May 20, 2024
Jason R. Nunn Director May 20, 2024

Recent Insider Transactions by Companies or Individuals for Regulus Therapeutics Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.